Phase 1/2 Study of 6MHP Vaccine and Ipilimumab for Advanced Melanoma

Share this content:
Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.
Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.

Title: A Phase I/II Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Advanced Melanoma (Mel62; 6PAC)1

Principal Investigator: Elizabeth Gaughan, MD, University of Virginia

Study Director: Craig L. Slingluff, Jr, MD, University of Virginia

Description: For this single-arm, open-table, phase 1/2 trial (ClinicalTrials.gov Identifier: NCT02385669), researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.

6MHP is made up of 6 peptides from melanoma proteins. The vaccine will be delivered intradermally and subcutaneously alongside ipilimumab 3 mg/kg once per 21 days.

The primary endpoints are safety, CD4+ T cell responses, and disease control rate.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02385669.

Status: This study is open and recruiting patients as of August 11, 2017.

This study is sponsored by Craig L Slingluff, Jr.

Reference

  1. Clinicaltrials.gov. A phase I/II trial to evaluate a peptide vaccine plus ipilimumab in patients with melanoma (Mel62; 6PAC).  NCT02385669. https://clinicaltrials.gov/ct2/show/NCT02385669. Accessed August 11, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters